| PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine? N Fusco, E Sajjadi, K Venetis, G Gaudioso, G Lopez, C Corti, EG Rocco, ... Genes 11 (7), 719, 2020 | 133 | 2020 |
| HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer K Venetis, E Crimini, E Sajjadi, C Corti, E Guerini-Rocco, G Viale, ... Frontiers in molecular biosciences 9, 834651, 2022 | 109 | 2022 |
| Breast cancer with bone metastasis: molecular insights and clinical management K Venetis, R Piciotti, E Sajjadi, M Invernizzi, S Morganti, C Criscitiello, ... Cells 10 (6), 1377, 2021 | 66 | 2021 |
| CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress C Corti, K Venetis, E Sajjadi, L Zattoni, G Curigliano, N Fusco Expert Opinion on Investigational Drugs 31 (6), 593-605, 2022 | 60 | 2022 |
| Impact of rehabilitation on breast cancer related fatigue: a pilot study M Invernizzi, A De Sire, L Lippi, K Venetis, E Sajjadi, F Gimigliano, ... Frontiers in Oncology 10, 556718, 2020 | 59 | 2020 |
| Improving HER2 testing reproducibility in HER2-low breast cancer E Sajjadi, K Venetis, M Ivanova, N Fusco Cancer Drug Resistance 5 (4), 882, 2022 | 57 | 2022 |
| Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients N Fusco, V Vaira, I Righi, E Sajjadi, K Venetis, G Lopez, M Cattaneo, ... Lung Cancer 150, 53-61, 2020 | 45 | 2020 |
| Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer M Ivanova, FM Porta, M D’Ercole, C Pescia, E Sajjadi, G Cursano, ... Virchows Archiv 484 (1), 3-14, 2024 | 39 | 2024 |
| Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization E Sajjadi, K Venetis, R Piciotti, M Invernizzi, E Guerini-Rocco, ... Cancer Cell International 21, 1-10, 2021 | 38 | 2021 |
| PTEN expression as a complementary biomarker for mismatch repair testing in breast cancer G Lopez, M Noale, C Corti, G Gaudioso, E Sajjadi, K Venetis, D Gambini, ... International journal of molecular sciences 21 (4), 1461, 2020 | 38 | 2020 |
| Cellular immunotherapy in breast cancer: The quest for consistent biomarkers K Venetis, M Invernizzi, E Sajjadi, G Curigliano, N Fusco Cancer treatment reviews 90, 102089, 2020 | 36 | 2020 |
| Biomarkers for precision immunotherapy in the metastatic setting: hope or reality? E Sajjadi, K Venetis, C Scatena, N Fusco Ecancermedicalscience 14, 1150, 2020 | 35 | 2020 |
| The evolving landscape of anatomic pathology P Pisapia, V L’Imperio, F Galuppini, E Sajjadi, A Russo, B Cerbelli, ... Critical Reviews in Oncology/Hematology 178, 103776, 2022 | 34 | 2022 |
| Determination of mismatch repair status in human cancer and its clinical significance: does one size fit all? C Corti, E Sajjadi, N Fusco Advances in Anatomic Pathology 26 (4), 270-279, 2019 | 34 | 2019 |
| Low-risk triple-negative breast cancers: Clinico-pathological and molecular features N Fusco, E Sajjadi, K Venetis, M Ivanova, S Andaloro, E Guerini-Rocco, ... Critical Reviews in Oncology/Hematology 172, 103643, 2022 | 33 | 2022 |
| Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology C Criscitiello, E Guerini-Rocco, G Viale, C Fumagalli, E Sajjadi, K Venetis, ... Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2022 | 31 | 2022 |
| Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers K Venetis, E Sajjadi, S Haricharan, N Fusco Translational Cancer Research 9 (7), 4060, 2020 | 31 | 2020 |
| Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists N Fusco, M Ragazzi, E Sajjadi, K Venetis, R Piciotti, S Morganti, ... Histology and histopathology 36 (12), 1235-1245, 2021 | 30 | 2021 |
| Efficacy of antiresorptive drugs on bone mineral density in post-menopausal women with early breast cancer receiving adjuvant aromatase inhibitors: a systematic review of … A de Sire, L Lippi, K Venetis, S Morganti, E Sajjadi, C Curci, ... Frontiers in Oncology 11, 829875, 2022 | 28 | 2022 |
| Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test E Sajjadi, E Guerini-Rocco, E De Camilli, O Pala, G Mazzarol, K Venetis, ... Frontiers in Molecular Biosciences 10, 1176309, 2023 | 24 | 2023 |
